Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$1.03 - $2.02 $688,474 - $1.35 Million
668,422 Added 14.51%
5,273,685 $5.75 Billion
Q2 2023

Aug 16, 2023

BUY
$0.82 - $2.49 $3.78 Million - $11.5 Million
4,605,263 New
4,605,263 $8.93 Billion

Others Institutions Holding XFOR

About X4 Pharmaceuticals, Inc


  • Ticker XFOR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,646,096
  • Market Cap $23.3M
  • Description
  • X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...
More about XFOR
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.